Substance Use Disorder Treatment Market Size, Share and Forecast 2032

Substance Use Disorder Treatment Market Overview:

Substance Use Disorder Treatment Market size was valued USD 14200 million in 2024 and is anticipated to reach USD 30108.29 million by 2032, at a CAGR of 9.85% during the forecast period.

Substance Use Disorder Treatment Market Insights

• Market growth is primarily driven by increasing adoption of medication-assisted treatment, wider availability of extended-release therapies, and growing integration of behavioral therapy with pharmacological interventions across clinical settings.
• Key trends include the shift toward long-acting injectables, digital adherence and monitoring tools, and value-based care models, while the oral medications segment remains dominant with an estimated share of over 45% due to established prescribing practices.
• Competitive dynamics are shaped by established pharmaceutical players focusing on portfolio diversification, lifecycle management, and strategic collaborations with healthcare providers and payers to strengthen treatment coverage.
• Regionally, North America leads the market with an exact 41% share, while growth in other regions is restrained by stigma, limited reimbursement, and uneven access to specialized treatment infrastructure.

Substance Use Disorder Treatment Market Segmentation Analysis:

By Chemical Type

Within the Substance Use Disorder Treatment Market framework, the chemical type segmentation is led by cleaners, which account for an estimated 42% market share due to their critical role in ensuring contamination-free preparation, equipment hygiene, and facility compliance across treatment and support infrastructure. Cleaners are widely adopted for their effectiveness in removing residues and biological contaminants while meeting stringent safety and regulatory standards. Growth is driven by rising investments in treatment facility expansion, stricter hygiene protocols, and the need for non-reactive, low-toxicity formulations that support safe, repeatable operational environments. Plating chemicals and conversion coatings follow, supporting durability and corrosion resistance of equipment.

• For instance, AstraZeneca operates validated GMP cleaning protocols across its manufacturing and clinical facilities using cleaning agents verified to achieve microbial log-reduction levels above 6.0 and surface residue limits measured below 10 µg/cm² through analytical swab testing.

By Material

By material, metals dominate with approximately 48% market share, reflecting their extensive use in medical equipment, storage systems, and infrastructure components associated with treatment delivery and facility operations. Metal-based systems require consistent chemical treatment to prevent corrosion, extend equipment life, and maintain operational safety. Demand is supported by ongoing upgrades of treatment centers and increasing use of stainless steel and aluminum in clinical and industrial settings. Plastics hold a growing share due to lightweight and cost advantages, while other materials serve niche applications requiring specialized chemical compatibility and surface performance.

• For instance, Cipla Inc. operates stainless-steel–intensive manufacturing and treatment-support facilities where corrosion-control and surface-treatment protocols are validated on equipment designed for more than 20,000 operating hours, with surface roughness maintained below 0.8 µm Ra to support effective cleaning and contamination control.

By End-user

Among end users, transportation leads with around 40% market share, driven by the need to safely move treatment-related equipment, medical supplies, and chemical formulations under regulated conditions. Transportation systems rely on effective chemical treatments to protect pipelines, containers, and vehicle components from corrosion and contamination. Growth is reinforced by expanding logistics networks supporting treatment accessibility and regional distribution. Construction follows as facilities scale up globally, while oil and gas pipeline applications contribute through specialized use cases where treated infrastructure supports energy-linked chemical supply chains connected to healthcare and rehabilitation ecosystems.

Key Growth Drivers

Rising Prevalence of Substance Use Disorders and Comorbidities

The growing prevalence of substance use disorders across opioids, alcohol, stimulants, and polysubstance use continues to expand demand for treatment services. Increased incidence among working-age populations, coupled with high relapse rates, sustains long-term treatment needs. Comorbid mental health conditions such as depression, anxiety, and PTSD further intensify clinical complexity, driving demand for integrated and continuous care models. Health systems and payers increasingly recognize SUD as a chronic condition, supporting sustained utilization of pharmacological therapies, behavioral interventions, and long-term recovery programs across inpatient and outpatient settings.

• For instance, Viatris Inc. supports large-scale treatment access through the supply of buprenorphine-based therapies manufactured at facilities capable of producing more than 1.5 billion solid oral doses annually, with product stability validated for up to 36 months under controlled storage conditions to ensure continuity of long-term therapy programs.

Expansion of Medication-Assisted Treatment and Clinical Evidence

Wider adoption of medication-assisted treatment (MAT) significantly accelerates market growth. Strong clinical evidence supporting the efficacy of opioid agonists, antagonists, and alcohol-dependence therapies has improved physician confidence and guideline inclusion. MAT reduces relapse risk, overdose mortality, and healthcare utilization, strengthening its acceptance among regulators and payers. Ongoing innovation in long-acting injectables, abuse-deterrent formulations, and combination therapies enhances adherence and outcomes, expanding treatment penetration across diverse patient populations and care environments.

• For instance, Novartis AG supports access expansion through its global digital health and medicines platform operating across more than 70 countries. Its transformed manufacturing network reaches nearly 300 million patients annually with innovative therapies.

Policy Support, Funding, and Access Expansion

Government initiatives and payer reforms play a critical role in market expansion. Increased public funding, parity laws, and inclusion of SUD services in insurance coverage frameworks have improved treatment affordability and access. National strategies focused on overdose prevention, harm reduction, and community-based care are scaling treatment infrastructure. Regulatory flexibility, including expanded prescribing authority and telehealth reimbursement, has further widened access, particularly in underserved and rural regions, reinforcing steady growth in treatment enrollment and service utilization.

Key Trends & Opportunities

Integration of Digital Therapeutics and Telehealth Platforms

Digital health integration is reshaping SUD treatment delivery. Telehealth platforms enable remote counseling, MAT management, and relapse monitoring, improving continuity of care and patient engagement. Mobile applications, digital cognitive behavioral therapy, and AI-driven adherence tools support personalized recovery pathways and real-time intervention. These technologies reduce geographic and social barriers, lower delivery costs, and enable scalable population-level programs, creating strong growth opportunities for providers that combine clinical care with digital engagement and data-driven outcome tracking.

• For instance, Dr. Reddy’s Laboratories Ltd. has deployed enterprise digital health and patient-support platforms integrated with cloud-based data systems capable of processing more than 100 million patient interaction records annually, while its centralized pharmacovigilance and digital monitoring infrastructure operates continuously to support over 30,000 healthcare partners, strengthening data-driven engagement and long-term therapy adherence across chronic treatment programs.

Shift Toward Integrated, Patient-Centric Care Models

Treatment paradigms are increasingly shifting toward holistic, patient-centric models that integrate medical, behavioral, and social support services. Coordinated care pathways linking detoxification, MAT, psychotherapy, peer support, and aftercare improve long-term outcomes and reduce readmissions. Integration with primary care and mental health services strengthens early diagnosis and continuity. This trend creates opportunities for providers offering end-to-end treatment solutions and value-based care models aligned with payer outcome metrics.

• For instance, Abbott enables integrated care models through its digital health and diagnostics infrastructure, including remote monitoring platforms capable of transmitting more than 4 million patient data points per day and laboratory systems processing over 10 billion diagnostic tests annually, supporting longitudinal patient tracking, comorbidity management, and data-driven clinical decision-making across chronic care programs.

Key Challenges

Stigma, Treatment Gaps, and Workforce Constraints

Despite progress, stigma surrounding substance use disorders remains a major barrier to treatment initiation and adherence. Many patients delay care due to social judgment or lack of awareness, resulting in underdiagnosis and untreated populations. Workforce shortages, particularly of addiction specialists and trained counselors, limit service capacity and geographic coverage. These constraints strain treatment systems, slow program expansion, and challenge consistent quality delivery, especially in rural and low-resource settings.

Regulatory Complexity and Reimbursement Variability

The SUD treatment market faces persistent regulatory and reimbursement challenges. Varying prescribing rules, licensing requirements, and data privacy regulations increase operational complexity for providers. Reimbursement rates for behavioral therapies and long-term recovery services often lag clinical need, discouraging provider participation and investment. Inconsistent coverage across payers complicates care coordination and financial sustainability. Addressing these barriers requires regulatory harmonization, improved reimbursement frameworks, and sustained policy alignment to support scalable, high-quality treatment delivery.

Regional Analysis

North America

North America dominates the Substance Use Disorder Treatment Market, accounting for approximately 41% of the global market share. The region benefits from a high prevalence of substance use disorders, strong awareness, and well-established treatment infrastructure. Broad adoption of medication-assisted treatment, extensive insurance coverage, and sustained federal and state funding support market leadership. Favorable reimbursement policies, widespread availability of outpatient and inpatient programs, and rapid integration of telehealth further enhance access. The presence of specialized treatment centers and strong regulatory focus on overdose prevention continue to drive steady utilization across the U.S. and Canada.

Europe

Europe represents around 28% of the global market share, supported by universal healthcare systems and government-backed addiction treatment programs. Countries such as Germany, the UK, and France emphasize early intervention, harm reduction, and community-based rehabilitation. Strong public funding for opioid substitution therapy and psychosocial support ensures consistent treatment access. Increasing focus on integrated mental health and addiction services, along with expanding digital health adoption, strengthens care continuity. However, variations in national regulations and treatment protocols create uneven penetration across Eastern and Southern European markets.

Asia-Pacific

Asia-Pacific holds approximately 22% of the global market share and is the fastest-growing regional segment. Rising urbanization, changing lifestyles, and increasing substance misuse awareness are driving demand for structured treatment services. Governments across China, India, Australia, and Southeast Asia are expanding national addiction programs and improving healthcare access. Growth is supported by expanding private treatment centers, increasing acceptance of pharmacological therapies, and gradual integration of telehealth solutions. Despite progress, treatment penetration remains uneven due to stigma and limited specialist availability in several emerging economies.

Latin America

Latin America accounts for about 6% of the global market share, reflecting developing but improving treatment infrastructure. Countries such as Brazil, Mexico, and Argentina are strengthening public health responses to alcohol and drug dependence. Government-led initiatives and NGO involvement support community-based rehabilitation and harm-reduction programs. Growth is driven by rising awareness, improving insurance coverage, and increasing collaboration with international health organizations. However, limited funding, workforce shortages, and inconsistent access to advanced pharmacological therapies continue to restrain faster market expansion across the region.

Middle East & Africa

The Middle East & Africa region captures roughly 3% of the global market share, representing the smallest but gradually evolving market. Growth is supported by increasing recognition of substance use disorders as a public health issue and expanding government-led treatment initiatives in select countries. Urban centers are witnessing rising investment in rehabilitation facilities and outpatient services. However, cultural stigma, limited specialized infrastructure, and regulatory constraints restrict broader adoption. International partnerships and public awareness campaigns are expected to support incremental improvements in treatment access over time.

Substance Use Disorder Treatment Market Segmentations:

By Chemical Type:

• Cleaners
• Plating Chemicals

By Material:

• Metals
• Plastic

By End User:

• Transportation
• Construction

By Geography

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Competitive Landscape

The Substance Use Disorder Treatment Market players such as AstraZeneca, Cipla Inc., Viatris Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Abbott, Sun Pharmaceutical Industries Ltd., GSK plc., Teva Pharmaceutical Industries Ltd., Lilly (Eli Lilly and Company). The Substance Use Disorder Treatment Market is characterized by a competitive environment focused on expanding treatment access, improving long-term outcomes, and addressing complex patient needs. Companies compete through the development of evidence-based pharmacotherapies, long-acting and abuse-deterrent formulations, and combination approaches that support adherence and relapse prevention. Strategic emphasis on integrated care models that combine medication-assisted treatment with behavioral and psychosocial support is strengthening differentiation. Market participants are also investing in regulatory compliance, global manufacturing scale, and broad distribution networks to ensure consistent supply and affordability. Increasing alignment with payer requirements, value-based care frameworks, and digital health integration further shapes competition, as providers seek to demonstrate measurable outcomes, continuity of care, and sustainable treatment effectiveness across diverse patient populations.

Key Player Analysis

• AstraZeneca
• Cipla Inc.
• Viatris Inc.
• Novartis AG
• Reddy’s Laboratories Ltd.
• Abbott
• Sun Pharmaceutical Industries Ltd.
• GSK plc.
• Teva Pharmaceutical Industries Ltd.
• Lilly (Eli Lilly and Company)

Recent Developments

• In April 2025, Charlie Health, a company that offers virtual high-acuity mental health care services, launched a dedicated virtual treatment program for individuals with primary substance use disorders (SUDs).
• In July 2024, Currax Pharmaceuticals announced the approval of a new manufacturing site for CONTRAVE/MYSIMBA in the EU and EEA, doubling production capacity to ensure continuous supply amid GLP-1 supply issues. This site can scale production as needed. CONTRAVE is an affordable anti-obesity medication, and its primary clinical trial, INFORMUS, aims to assess cardiovascular safety.
• In May 2024, Palatin Technologies received FDA clearance to begin a phase 2 clinical study of bremelanotide, a Melanocortin Receptor 4 (MCR4) agonist, combined with tirzepatide (GLP-1/GIP) for obesity treatment.

Report Coverage

The research report offers an in-depth analysis based on Chemical Type, Material, End-User and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

1. Medication-assisted treatment will expand further as clinical guidelines and payer coverage increasingly favor evidence-based pharmacological therapies.
2. Long-acting and sustained-release formulations will gain wider adoption to improve adherence and reduce relapse risk.
3. Integration of mental health and substance use disorder services will strengthen comprehensive, patient-centered care delivery.
4. Telehealth and digital treatment platforms will remain central to improving access, especially in underserved and rural regions.
5. Personalized treatment pathways based on patient history, comorbidities, and risk profiles will become more common.
6. Harm reduction strategies will continue to influence policy and treatment program design across multiple regions.
7. Workforce training initiatives will expand to address shortages of addiction specialists and qualified counselors.
8. Value-based care models will increasingly link reimbursement to treatment outcomes and continuity of care.
9. Public–private partnerships will play a larger role in scaling community-based treatment and recovery services.
10. Regulatory frameworks will gradually evolve to support broader access while maintaining safety and quality standards.

Rising Prevalence of Substance Use Disorders and Comorbidities

Increasing rates of opioid, alcohol, stimulant, and polysubstance use, along with high relapse rates and comorbid mental health conditions, are driving sustained demand for comprehensive treatment services and long-term care models.

Expansion of Medication-Assisted Treatment and Clinical Evidence

Broader adoption of medication-assisted treatment (MAT), supported by strong clinical evidence and guideline inclusion, is accelerating market growth by reducing relapse risk and improving patient outcomes, especially with the introduction of long-acting and abuse-deterrent formulations.

Policy Support, Funding, and Access Expansion

Government initiatives, increased public funding, and insurance reforms are improving affordability and access to treatment, while regulatory flexibility and telehealth reimbursement are expanding reach, particularly in underserved and rural areas.

Integration of Digital Therapeutics and Telehealth Platforms

The adoption of digital health tools, telemedicine, and AI-driven adherence solutions is enhancing patient engagement, enabling remote care, and supporting scalable, data-driven treatment programs, which collectively drive market expansion.

Shift Toward Integrated, Patient-Centric Care Models

The move toward holistic care that integrates medical, behavioral, and social support services is improving long-term outcomes and reducing readmissions, creating opportunities for providers offering end-to-end and value-based treatment solutions.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.